Yasser Riazalhosseini

Home / Investigators  / Yasser Riazalhosseini

Yasser Riazalhosseini

Assistant Professor, Department of Human Genetics

Phone: (514) 398-1784

740 Dr Penfield Ave, Room 4203
Montréal, Québec, Canada, H3A 0G1


While collaborating on genome characterization of different tumor entities, research in the lab is focused on following topics:

Comprehensive molecular understanding of renal cell carcinoma
Renal cell carcinoma (RCC) is the most common form of kidney tumors. RCC has different subtypes with clear cell (ccRCC; conventional) being the most frequently diagnosed subtype accounting for 75-80% of RCCs. The incidence of RCC is increasing worldwide, but there is no biological marker for routine clinical use. Furthermore, it is essential to identify novel therapies as RCCs are resistant to conventional chemo- and radio-therapy.

We have recently generated comprehensive genome, epigenome and transcriptome landscapes of ccRCC. In an integrative manner, our lab is dissecting these profiles in order to identify molecular aberrations that possess cancer-driving activities. We have also extended our research to characterize molecular aberrations of other subtypes of RCC including papillary and chromophobe tumors, whose genetic abnormalities are less understood.

Post-transcriptional regulatory programs in cancer
In parallel to analyzing (epi)genome patterns, as factors governing gene expression at transcriptional level, we are investigating role of non-coding transcripts including long non-coding RNAs and microRNAs (miRNAs) as well as RNA binding proteins (RBPs) in post-transcriptional deregulation of cancer transcriptome. Specifically, we combine cancer-associated gene expression patterns with regulatory networks of miRNAs and RBPs, and apply quantitative approaches to these profiles in order to predict factors whose aberrant function can explain the abnormal transcriptome of tumor samples. These potentially “master regulators” are then subjected to experimental verification for their driver activities.

Investigating intra-tumoral heterogeneity and its contribution to metastasis
Approaches to stratifying risk or tailoring therapy for individual cancer patients based on the molecular profile of their tumor biopsy are complicated by the existence of genetic heterogeneity (representing distinct populations of cancer cells with different sets of mutations; subclones) both within and across tumors. Furthermore, across tumor sites, genomes of disseminated cancer cells may have similarities at the onset of metastatic disease, but substantial changes in the genetic composition occur spatially and over time, supporting the suggestion that the expansion of aggressive driver clone(s) and the emergence of relevant subclones correlate with development of incurable disease and potential therapeutic resistance. Our lab has optimized protocols of NGS on minutes amount of DNA as well as on DNA isolated from Formalin-fixed, paraffin-embedded (FFPE) samples providing an opportunity to analyze archived primary tumors of patients affected with metastatic or recurrent disease. We analyze the heterogeneous clonal composition of primary and metastatic tumors in order to investigate genomic evolution of metastasis.

Recent Publications

  • Perron, G, Jandaghi, P, Moslemi, E, Nishimura, T, Rajaee, M, Alkallas, R et al.. Pan-cancer analysis of mRNA stability for decoding tumour post-transcriptional programs. Commun Biol. 2022;5 (1):851. doi: 10.1038/s42003-022-03796-w. PubMed PMID:35987939 PubMed Central PMC9392771.
  • Yang, H, Messina-Pacheco, J, Corredor, ALG, Gregorieff, A, Liu, JL, Nehme, A et al.. An integrated model of acinar to ductal metaplasia-related N7-methyladenosine regulators predicts prognosis and immunotherapy in pancreatic carcinoma based on digital spatial profiling. Front Immunol. 2022;13 :961457. doi: 10.3389/fimmu.2022.961457. PubMed PMID:35979350 PubMed Central PMC9377277.
  • Daniel, P, Meehan, B, Sabri, S, Jamali, F, Sarkaria, JN, Choi, D et al.. Detection of temozolomide-induced hypermutation and response to PD-1 checkpoint inhibitor in recurrent glioblastoma. Neurooncol Adv. 2022;4 (1):vdac076. doi: 10.1093/noajnl/vdac076. PubMed PMID:35795471 PubMed Central PMC9252128.
  • McIntyre, WB, Karimzadeh, M, Riazalhosseini, Y, Khazaei, M, Fehlings, MG. Cell-Cell Contact Mediates Gene Expression and Fate Choice of Human Neural Stem/Progenitor Cells. Cells. 2022;11 (11):. doi: 10.3390/cells11111741. PubMed PMID:35681435 PubMed Central PMC9179342.
  • Assidicky, R, Tokat, UM, Tarman, IO, Saatci, O, Ersan, PG, Raza, U et al.. Targeting HIF1-alpha/miR-326/ITGA5 axis potentiates chemotherapy response in triple-negative breast cancer. Breast Cancer Res Treat. 2022;193 (2):331-348. doi: 10.1007/s10549-022-06569-5. PubMed PMID:35338412 PubMed Central PMC9389626.
  • Glennon, KI, Maralani, M, Abdian, N, Paccard, A, Montermini, L, Nam, AJ et al.. Rational Development of Liquid Biopsy Analysis in Renal Cell Carcinoma. Cancers (Basel). 2021;13 (22):. doi: 10.3390/cancers13225825. PubMed PMID:34830979 PubMed Central PMC8616270.
  • Bergholtz, H, Carter, JM, Cesano, A, Cheang, MCU, Church, SE, Divakar, P et al.. Best Practices for Spatial Profiling for Breast Cancer Research with the GeoMx® Digital Spatial Profiler. Cancers (Basel). 2021;13 (17):. doi: 10.3390/cancers13174456. PubMed PMID:34503266 PubMed Central PMC8431590.
  • Willis-Owen, SAG, Domingo-Sabugo, C, Starren, E, Liang, L, Freidin, MB, Arseneault, M et al.. Y disruption, autosomal hypomethylation and poor male lung cancer survival. Sci Rep. 2021;11 (1):12453. doi: 10.1038/s41598-021-91907-8. PubMed PMID:34127738 PubMed Central PMC8203787.
  • Khalesi, R, Razmara, E, Asgaritarghi, G, Tavasoli, AR, Riazalhosseini, Y, Auld, D et al.. Novel manifestations of Warburg micro syndrome type 1 caused by a new splicing variant of RAB3GAP1: a case report. BMC Neurol. 2021;21 (1):180. doi: 10.1186/s12883-021-02204-w. PubMed PMID:33910511 PubMed Central PMC8080372.
  • Tawil, N, Bassawon, R, Meehan, B, Nehme, A, Montermini, L, Gayden, T et al.. Glioblastoma cell populations with distinct oncogenic programs release podoplanin as procoagulant extracellular vesicles. Blood Adv. 2021;5 (6):1682-1694. doi: 10.1182/bloodadvances.2020002998. PubMed PMID:33720339 PubMed Central PMC7993100.
Search PubMed